Stockhub

Catalyst Pharmaceuticals, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

19 August 2022

12 August 2022

27 July 2022

  • curprev 20:1520:15, 27 July 2022‎ Chris talk contribs‎ 1,065 bytes +1,065‎ Created page with "Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatm..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Catalyst_Pharmaceuticals,_Inc.’